Research
Creating an online cervical cancer programme to avoid disruptions to care during COVID-19
15 November 2022
2022 Access to Medicine Index: special report
Is the industry making progress on improving access to medicine?
This Special Report, published as part of the 2022 Access to Medicine Index, takes a longitudinal look at the pharmaceutical industry. It compares this year's data with data from previous Indexes, highlighting both areas of progress and areas of stagnation.
Date
18 November 2022
The Access to Medicine Index was first published in 2008, with the 2022 Index marking its eighth edition. Since its launch, the Index has provided insights into how 20 of the world’s largest pharmaceutical companies perform on ensuring access to medicine in low- and middle-income countries (LMICs).
This nine-page Special Report, available for download as an extract from the 2022 Index, shines a light on the extent to which the industry is making progress on improving access to medicine, and whether it is making progress towards the UN's Sustainable Development Goal 3 (SDG3) for 2030, despite the challenges of the COVID-19 pandemic. It looks across all the areas identified as key access-to-medicine priorities and assesses where progress has been made – and where it has not.
As the methodology for the 2022 Index has a high level of continuity with the previous Index, this allows for direct comparisons, and greater insight into change over time. Where possible, the Special Report also draws on data from previous Indexes.
What’s in the 2022 Special Report?
Governance of Access
In which areas have companies made a shift from indirect to direct top-level accountability for access to medicine and to what extent have companies increased and integrated an access-to-medicine mindset in their business operations? How does the industry perform in terms of ensuring compliance and incentivising good ethical conduct by sales agents?
Research & Development
In comparison to 2021, what is the breakdown of the pipeline and to what extent have companies increased R&D projects to address diseases in scope of the Index?
Product Delivery
How have companies developed their access strategies and how are companies making progress in non-exclusive voluntary licensing and patent transparency, in comparison to previous Indexes?
